FDA Cannot Regulate Stem Cell Treatments, DC Circ. Hears

Law360, Washington (October 21, 2013, 5:28 PM EDT) -- Regenerative Sciences LLC on Monday blasted the U.S. Food and Drug Administration's attempt to regulate its stem cell treatments as a drug, telling a D.C. Circuit panel that the agency doesn't have the authority to oversee its medical practices.

Regenerative Sciences' counsel Andrew S. Ittleman accused the agency of trying to gain “limitless authority” over the medical practice by claiming its Regenexx procedure had violated the Federal Food, Drug and Cosmetic Act by shipping its components across state lines.

The Regenexx procedure — which uses a...
To view the full article, register now.

Related

Sections

Case Information

Case Title

USA v. Regenerative Sciences, LLC, et al


Case Number

12-5254

Court

Appellate - DC Circuit

Nature of Suit

1890 Other Statutory Actions

Date Filed

August 16, 2012

Law Firms

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.